AbbVie's elagolix could put pressure on budgets, ICER estimates

AbbVie's experimental endometriosis drug elagolix could put pressure on healthcare budgets even if priced within commonly used cost-effectiveness thresholds, suggests a new draft report from the Institute for Clinical and Economic Review (ICER), a watchdog group on drug costs.